Valproate (Paternal exposure)

Severe cognitive developmental delay (Mental retardation) (> 6 years old)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18944
R80557
Meng_Taiwan (Controls unexposed, sick), 2026 Developmental Coordination Disorder - At least 2 diagnoses on different dates ICD-9 and ICD-10: F70.xx-F79.xx - Follow up: between 6 and 12 years Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) population based cohort retrospective unexposed, sick Adjustment: Yes Paternal ASMs: monotherapy 1.09 [0.57;2.09] 10/543   4,864/500,498 4,874 543
ref
S18948
R80587
Razaz_Sweden, 2026 Intellectual disability (ID) - One diagnosis ICD-10 code for ID: F70– F79 - Median age at the end of follow-up: 6.6 years Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) population based cohort retrospective exposed to other treatment, sick Adjustment: Yes Paternal ASMs: monotherapy 1.20 [0.65;2.21] 22/1,500   33/2,906 55 1,500
ref
S18654
R79278
Botton, 2025 Intellectual Developmental Disorder - ICD10: F70-F79 - Median follow up (years): 11.9 (IQR [10.3 - 13.3]) for valproate; 11.2 (IQR [9.9 - 12.8]) for control Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) retrospective cohort (claims database) exposed to other treatment, sick Adjustment: Yes Paternal ASMs: monotherapy 2.07 [0.78;5.53] 25/3,484   5/2,041 30 3,484
ref
S18646
R79289
Christensen (Controls exposed to LTG/LEV), 2024 Intellectual disability - ICD-10 codes F70-79 - Median age [IQR] age at the end of follow-up: 10.6 [5.4-15.0] years for valproate; 5.5 [2.7-9.3] years for controls Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) population based cohort retrospective exposed to other treatment, sick Adjustment: Yes Paternal ASMs: monotherapy 1.85 [0.72;4.76] 21/961   7/1,401 28 961
ref
Total 4 studies 1.35 [0.93;1.95] 4,987 6,488
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Meng_Taiwan (Controls unexposed, sick), 2026Meng_Taiwan, 2026 1 1.09[0.57; 2.09]4,87454333%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: low Razaz_Sweden, 2026Razaz_Sweden, 2026 1.20[0.65; 2.21]551,50037%ROB confusion: seriousROB selection: unclearROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Botton, 2025Botton, 2025 2.07[0.78; 5.53]303,48414%ROB confusion: moderateROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Christensen (Controls exposed to LTG/LEV), 2024Christensen, 2024 2 1.85[0.72; 4.76]2896116%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Total (4 studies) I2 = 0% 1.35[0.93; 1.95]4,9876,4880.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick; 2: Controls exposed to LTG/LEV;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.35[0.93; 1.95]4,9876,4880%NAMeng_Taiwan (Controls unexposed, sick), 2026 Razaz_Sweden, 2026 Botton, 2025 Christensen (Controls exposed to LTG/LEV), 2024 4 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.09[0.57; 2.09]4,874543 -NAMeng_Taiwan (Controls unexposed, sick), 2026 1 exposed to other treatment, sickexposed to other treatment, sick 1.49[0.95; 2.35]1135,9450%NARazaz_Sweden, 2026 Botton, 2025 Christensen (Controls exposed to LTG/LEV), 2024 3 Tags Adjustment   - Yes  - Yes 1.35[0.93; 1.95]4,9876,4880%NAMeng_Taiwan (Controls unexposed, sick), 2026 Razaz_Sweden, 2026 Botton, 2025 Christensen (Controls exposed to LTG/LEV), 2024 4 Paternal ASMs   - monotherapy  - monotherapy 1.35[0.93; 1.95]4,9876,4880%NAMeng_Taiwan (Controls unexposed, sick), 2026 Razaz_Sweden, 2026 Botton, 2025 Christensen (Controls exposed to LTG/LEV), 2024 4 All studiesAll studies 1.35[0.93; 1.95]4,9876,4880%NAMeng_Taiwan (Controls unexposed, sick), 2026 Razaz_Sweden, 2026 Botton, 2025 Christensen (Controls exposed to LTG/LEV), 2024 40.55.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-1.21.50.6000.000Meng_Taiwan (Controls unexposed, sick), 2026Razaz_Sweden, 2026Botton, 2025Christensen (Controls exposed to LTG/LEV), 2024

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.09[0.57; 2.09]4,874543 -NAMeng_Taiwan (Controls unexposed, sick), 2026 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.49[0.95; 2.35]1135,9450%NARazaz_Sweden, 2026 Botton, 2025 Christensen (Controls exposed to LTG/LEV), 2024 30.510.01.0